Design-Zyme is a privately-owned boutique biotech that has been in operation since 2015. Our team of talented experts have developed a new generation of vaccines designed to improve human health resulting in a robust IP portfolio. Our breakthrough vaccine technologies are driving revolutionary new approaches resulting in a pipeline that includes safe solutions for Opioid Use Disorder, Lyme Disease, and Chlamydia.
Design-Zyme strives to be at the forefront of the next generation of safer and broader vaccine platforms designed to be effective against multiplexed health threats. We are committed to making a difference in the world through our research and development of next-generation vaccines.
Our Mission
Experienced Leadership
At Design-Zyme LLC, our team is made up of experienced leaders in the biotechnology industry. Our researchers and scientists have a passion for creating innovative solutions to global health problems.
​​Our journey at Design-Zyme LLC began as a DARPA-initiated effort to improve human health monitoring. This pioneering work resulted in a general approach for the in vitro glycosylation of proteins to enhance enzyme stability for biosensor fabrication. This patented technology also proved invaluable for attaching carbohydrate adjuvants to protein-based vaccines.
​
Today, we are at the forefront of vaccine innovation, crafting new treatments to combat human disease. Our pipeline includes best-in-class polyvalent vaccines for opioid use disorder (OUD) and Lyme Disease. Our vaccines are extremely safe and designed to remain effective against present and future disease variants. At Design-Zyme, we believe in making a positive impact on global health and are unwavering in our dedication to pioneering innovative research that truly makes a difference.
